Consensus or Controversy? Clinical Investigators Provide Perspectives on Practical Issues and Ongoing Research Related to the Management of Breast Cancer — A Special Audio Supplement


MODULE 1: Optimal Treatment Strategies for Patients with Localized HER2-Positive Breast Cancer (BC)

Track 1: Choice of adjuvant anti-HER2 targeted therapy for patients with localized HER2-positive BC
Track 2: Optimal duration of adjuvant trastuzumab therapy
Track 3: Role of adjuvant pertuzumab for patients with ER-negative, HER2-positive BC
Track 4: Perspective on the use of extended adjuvant neratinib therapy
Track 5: Role of anthracyclines for HER2-positive BC in the (neo)adjuvant setting
Track 6: Approach to adjuvant therapy for patients with small, node-negative, HER2-positive BC

MODULE 2: Current Role of Genomic Assays in the Management of ER-Positive Early BC

Track 7: TAILORx trial: Adjuvant endocrine therapy is noninferior to chemoendocrine therapy for patients with hormone receptor-positive, HER2-negative, node-negative early BC with an intermediate 21-gene Recurrence Score® (RS) of 11 to 25
Track 8: Clinical implications of the results of the TAILORx study
Track 9: Use of ovarian suppression instead of chemotherapy for premenopausal women with an intermediate RS of 18 to 25
Track 10: Role of genomic assays in decision-making for patients with node-positive BC
Track 11: Utility of the 21-gene RS in the neoadjuvant setting

MODULE 3: Therapeutic Considerations for Patients with ER-Positive, HER2-Negative Metastatic BC (mBC)

Track 12: Management of de novo ER-positive, HER2-negative mBC
Track 13: Therapeutic approach for patients who develop metastatic disease after adjuvant endocrine therapy
Track 14: Selection of CDK4/6 inhibitors for patients with ER-positive mBC
Track 15: Therapeutic options for patients with ER-positive mBC who experience disease relapse after treatment with a CDK4/6 inhibitor

MODULE 4: Treatment of HER2-Positive mBC

Track 16: Management of HER2-positive mBC
Track 17: Efficacy of CDK4/6 inhibitors in patients with ER-positive, HER2-positive mBC
Track 18: Treatment options for patients with ER-positive, HER2-positive mBC experiencing disease progression after first-line therapy
Track 19: Activity and tolerability of neratinib for HER2-positive mBC

MODULE 5: Role of PARP Inhibition in the Management of BC

Track 20: Indications for BRCA mutation testing in patients with mBC
Track 21: Choice of olaparib versus chemotherapy for patients with triple-negative BC and a germline BRCA mutation
Track 22: Viewpoint on the efficacy of PARP inhibitors for patients with ER-positive, HER2-negative mBC and a BRCA germline mutation
Track 23: Therapeutic approach for patients with ER-positive, HER2-negative mBC and a BRCA2 germline mutation who experience disease progression after first-line therapy

MODULE 6: Emerging Role of Immune Checkpoint Inhibitors for patients with BC

Track 24: Selection of patients for immune checkpoint inhibitor therapy
Track 25: Perspective on the use of immune checkpoint inhibitors for patients with preexisting autoimmune disease
Harold J Burstein, MD, PhD
Associate Professor of Medicine
Harvard Medical School
Breast Oncology Center
Dana-Farber Cancer Institute
Boston, Massachusetts
Angelo Di Leo, MD, PhD
Head of the Sandro Pitigliani Department of Medical Oncology
Hospital of Prato
Istituto Toscano Tumori
Prato, Italy
Sara A Hurvitz, MD
Associate Professor of Medicine
Director, Breast Oncology Program
Division of Hematology/Oncology
University of California, Los Angeles
Medical Director, Jonsson Comprehensive Cancer Center Clinical Research Unit
Los Angeles, California
Co-Director, Santa Monica-UCLA Outpatient Oncology Practices
Santa Monica, California
Mark Robson, MD
Clinic Director, Clinical Genetics Service
Associate Attending Physician
Clinical Genetics and Breast Cancer Medicine
Associate Member
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine
Weill Medical College of Cornell University
New York, New York
Hope S Rugo, MD
Professor of Medicine
Director, Breast Oncology and Clinical Trials Education
University of California, San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, California
George W Sledge Jr, MD
Professor of Medicine
Chief, Division of Oncology
Department of Medicine
Stanford University School of Medicine
Stanford, California
Neil Love, MD
Research To Practice
Miami, Florida